WEILL CORNELL SCIENTISTS REVEAL HOW THE PROTEIN WORKS AND HOW THE DRUG GUMS IT UP, OFFERING NEW HOPE FOR TREATMENT OF AGGRESSIVE CANCER
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
In the journal Cell Reports, published today online, the scientists describe how the powerful master regulatory transcription factor Bcl6 regulates the genome, ensuring that aggressive lymphomas survive and thrive. They also show how the Bcl6 inhibitor, developed at Weill Cornell, effectively gums up the protein, stopping it from working.
While Bcl6 is active in a number of cancers, including leukemia and breast cancer, work testing a Bcl6 inhibitor is most advanced in DLBCL. “That’s because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,” says the study’s senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology/Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.
Dr. Melnick developed the first BCL6 inhibitors nine years ago, and has continued to improve upon the design of these drugs so they could be used to treat cancer patients. He has since collaborated with colleagues at many institutions in a systemic effort to understand how both Bcl6 and its inhibitor drugs function.
In a study published in March in Nature Immunology, Dr. Melnick and his team reported that it is possible to shut down Bcl6 in DLBCL without affecting its vital role in the T cells and macrophages needed to support a healthy immune system. The protein has long been considered too complex to target with a drug as it also is crucial to proper function of many immune system cells, not just B cells gone bad.
That finding suggested Bcl6 inhibiting drugs may have few side effects, says Dr. Melnick, who is also a hematologist-oncologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
The latest study was designed to understand exactly how Bcl6 promotes DLBCL.
Transcription factors are responsible for either inhibiting or promoting the expression of genes, and master regulatory transcription factors are like transcription factors on steroids: their actions regulate thousands of genes in different kinds of cells. Bcl6 can control the type of immune cell that develops in the bone marrow — pushing them to become B cells, T cells, or macrophages — and it has a primary role in the developmental phase of B cells, during which they generate specific antibodies against pathogens.
The researchers found that in order to help B cells produce antibodies against an infection, Bcl6 “builds a huge shopping mall-style complex” that sits on top of a stretch of the genome. By binding onto these genes, Bcl6 deactivates the DNA, stopping genes from producing RNA and proteins. “Bcl6 acts like a barcode reader. When it sees that barcode — the DNA sequence — it attaches there,” Dr. Melnick.
Normally, the protein complex goes away after an immune reaction has been successfully mounted against the pathogen. But when it doesn’t, and remains stuck to the genes, DLBCL can result. That’s because Bcl6 is inhibiting genes that stop cells from dividing and that sense damage to the genome, Dr. Melnick says. “We now know the genes that Bcl6 is repressing and how that helps lymphoma develop and survive.”
Bcl6 also has a second, independent function that Dr. Melnick says acts like a switch on railroad track that routes a train in one direction or another. One track is needed when antibodies are required for an immune response, while the other keeps B cells in a constant state of division.
The researchers found that in order for DLBCL to survive, Bcl6 needs to maintain both its shopping mall protein complex and keep the train tracks on the path toward B cell division.
To their surprise, they also found that both the complex and the train switch attach to the Bcl6 protein at the same site. “They fit into the same keyholes on Bcl6,” Dr. Melnick says. “There are two identical binding sites on the protein surface.”
Even better, the Bcl6 inhibitor they developed was designed to fit into that same keyhole.
“This is wonderfully serendipitous — our drug just happens to be able to overcome both of the biological mechanisms that are key to survival of aggressive lymphoma,” Dr. Melnick says, adding that the inhibitor completely eradicated DLBCL in mice in a short time, with no detectable side effects.
The Latest Bing News on:
Lymphoma
- Tell Me Something Good: Time To Pay It Forwardon April 26, 2024 at 4:00 pm
The last thing Joey Bearup needed as he entered his teen years was Hodgkin’s Lymphoma. All he wanted to do was to play some hoops and hang with his friends.
- A Cancer Drug that Impacted My Life for SLLon April 26, 2024 at 10:00 am
After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive.
- Paw Wash for a Cure to benefit the Leukemia & Lymphoma Societyon April 26, 2024 at 7:46 am
Booms and air raid sirens sounded in Jerusalem early Sunday after Iran launched dozens of drones and ballistic missiles toward Israel in an unprecedented revenge ...
- CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumorson April 25, 2024 at 11:30 pm
For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical hematopoietic stem-cell ...
- The Long and Winding Road Leading to My Non-Hodgkin Lymphomaon April 25, 2024 at 10:00 am
My cancer diagnosis of non-Hodgkin lymphoma took a circuitous route that would make the greatest explorer get lost, even with a compass and map. It all began with a tingling in my left hand. Month ...
- A Close Look at Hodgkin Lymphoma Treatment: Burke Reviews a Phase 2 Studyon April 24, 2024 at 12:11 pm
John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin ...
- 25-Year-Old Shares Subtle Lymphoma Symptoms That Were Misdiagnosedon April 24, 2024 at 9:25 am
"My mind went blank almost," said 25-year-old Jace Yawnick of being told he has lymphoma after being misdiagnosed.
- 25-Year-Old's Cough Was First Sign of Non-Hodgkin Lymphoma: 'Smacked in the Face with the News' (Exclusive)on April 23, 2024 at 2:51 pm
Jace Yawnick was diagnosed with non-Hodgkin lymphoma — now he is creating a nonprofit to help other cancer patients pay for treatment ...
- SEEN: Leukemia & Lymphoma Society Big Climb 2024on April 20, 2024 at 10:54 am
Were You Seen at the Leukemia & Lymphoma Society Big Climb at the Corning Tower on Saturday, April 20th, 2024, in Albany?
- Pittsburgh-area high school students raise $800K for Leukemia and Lymphoma Societyon April 18, 2024 at 5:05 pm
PINE TOWNSHIP, Pa. (KDKA) -- The Leukemia and Lymphoma Society recently recognized several fundraising teams for collecting a total of $802,000 for the nonprofit organization. And those teams are ...
The Latest Google Headlines on:
Lymphoma
[google_news title=”” keyword=”Lymphoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
TREATMENT OF AGGRESSIVE CANCER
- Dr. Kyri Mosley Had Cancer. Now She’s Building A Cookie Empireon April 26, 2024 at 1:26 pm
Dr. Kyri Mosley poses for a photograph with her products. Lauren Liz. Imagine being diagnosed with stage 4 cancer and you aren’t even fifty years old. You still want to see the ...
- King Charles III Returning to Public Duties After Cancer Diagnosison April 26, 2024 at 10:44 am
Nearly three months after King Charles III's cancer diagnosis, Buckingham Palace announced when the 75-year-old will return to public-facing duties.
- Markey’s Yang awarded $3M to study melanoma treatment targeton April 26, 2024 at 8:00 am
University of Kentucky Markey Cancer Center researcher Jin-Ming Yang, Ph.D., was recently awarded a $3 million, five-year grant from the National Cancer Institute (NCI) to support research focused on ...
- Kurt Williams starts radiation treatment for prostate canceron April 25, 2024 at 11:06 am
Today is the day! Today is the first day of my radiation treatment at Sentara's Oncology and Radiation department.
- Study identifies driver of liver cancer that could be target for treatmenton April 25, 2024 at 2:00 am
Inhibiting a certain protein in mice reduced obesity-induced liver tumor development, Yale researchers found. It could reveal a future treatment route.
- How mRNA Is Rewriting the Rules of Cancer Treatmenton April 24, 2024 at 2:24 pm
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments. What if training your immune system to ...
- Researchers identify novel gene networks associated with aggressive type of breast canceron April 24, 2024 at 11:10 am
Breast cancer is the second-most common cancer diagnosis for U.S. women, and the second-leading cause of female cancer deaths. In recent years, breast cancer treatments have improved significantly, ...
- Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatmenton April 23, 2024 at 10:30 pm
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment ...
- Potential new treatment strategy for aggressive leukemiaon April 18, 2024 at 7:11 am
Scientists have found a potential treatment strategy for an aggressive type of leukemia by targeting enzymes used by cells to sense and adapt to oxygen levels.
- 'Shopaholic' author Sophie Kinsella diagnosed with 'aggressive' brain canceron April 18, 2024 at 6:33 am
Sophie Kinsella, author of the "Shopaholic" book series, has revealed she is battling an "aggressive" form of brain cancer.
The Latest Google Headlines on:
TREATMENT OF AGGRESSIVE CANCER
[google_news title=”” keyword=”TREATMENT OF AGGRESSIVE CANCER” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]